Superbugs & Superdrugs - A Focus on Antibacterials

Now in its 14th year, this well established antibacterial event promises to be the perfect forum for networking and problem solving with senior industry executives from the pharmaceutical sector.
 
Jan. 10, 2012 - PRLog -- SMi present their 14th annual conference on...
Superbugs & Superdrugs
A Focus on Antibacterials
5-6 March 2012, Copthorne Tara Hotel, Central London, UK


Now in its 14th year, this well established antibacterial event promises to be the perfect forum for networking and problem solving with senior industry executives from the pharmaceutical sector.

The event will be made up of case-study focused presentations, highlighting success stories and lessons to be learnt. With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important and this event will be the perfect opportunity to be kept updated with advances in the antibacterial sector.

Key Benefits of Attending:

•   Developments of specific-spectrum, anti-staphyloccal agents using in-vitro, in-vivo and human clinical data
•   Evaluating methods to identify beta-lactam synergists and modification to counter bacterial resistance
•   Discussing anti(myco) bacterial drug discovery and development in TB research
•   Exploring new perspectives on the treatment of CDI
•   Updates in anti-fungal and vaccine therapies
•   Assess monoclonal antibody prophylaxis as an alternative approach
•   Combating antibacterial resistance in developing markets


Key Presentations Include:

Development of vaccines for the prevention of antibiotic-resistant bacterial infections
•   Identification of vaccine targets for bacterial pathogens
•   Preclinical evaluation of candidate vaccines
•   Focus on staphylococcus aurues and Clostridum difficle
Jon Heinrichs, Director, Microbial Vaccines, Merck

Novel LpxC inhibitors for treatment of gram-negative infections
•   The SAR of a new series of LpxC inhibitors
•   PK and strategies to lower human dose projections
•   X-ray crystallographic analysis of bound inhibitors
•   MIC90s for multiple gram-negatives
Justin Montgomery, Senior Principal Scientist, Pfizer


For further details and the full programme visit http://www.smi-online.co.uk/2012superbugs16.asp
End
Source: » Follow
Email:***@smi-online.co.uk Email Verified
Tags:Pharmaceutical, Medical, Health, Superbugs, Superdrugs, Antibacterial
Industry:Biotech, Health, Medical
Location:England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share